EXOME

all the information, none of the junk | biotech • healthcare • life sciences

CTI Gets $38M From Stock Sale

Cell Therapeutics raised $38.1 million through its underwritten public offering. The company (NASDAQ: CTIC) sold 29.3 million shares at $1.30 apiece, plus warrants to buy shares. The price was about a 20 percent discount to the $1.63 per share market closing price before the deal was announced. This money will be used to pay down some of the company’s $66 million in debt, and keep operating while it awaits word from the FDA on whether it will approve the company’s pixantrone treatment for non-Hodgkin’s lymphoma.